By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Boehringer Ingelheim Corporation 

P.O. Box 368
900 Ridgebury Road
Ridgefield  Connecticut  06877-0368  U.S.A.
Phone: 203-798-99-88 Fax: 203-791-62-34


SEARCH JOBS








Company News
Boehringer Ingelheim Corporation Initiates Global Phase 3 Study Investigating Nintedanib* In Patients With Colorectal Cancer Refractory To Standard Treatments 10/21/2014 7:14:03 AM
Boehringer Ingelheim Corporation Wins FDA Approval For Lung Disease Drug Ofev 10/15/2014 3:14:19 PM
Boehringer Ingelheim Corporation And Americares Partner To Expand Product Donations Program Globally 10/15/2014 10:49:17 AM
Boehringer Ingelheim Corporation Release: New COPD Maintenance Treatment Striverdi® Respimat® (olodaterol) Inhalation Spray Now Available in U.S. Pharmacies 10/8/2014 8:15:53 AM
Boehringer Ingelheim Corporation To Create 100 New Jobs With $125 Million+ Site Expansion 10/1/2014 6:49:45 AM
Boehringer Ingelheim Corporation's Afatinib Meets Primary Endpoint In Phase 3 Study Of Head And Neck Cancer 9/29/2014 7:15:13 AM
Boehringer Ingelheim Corporation Release: Nintedanib* Receives Positive CHMP Opinion For Second-Line Treatment Of Patients With Adenocarcinoma Of The Lung 9/26/2014 8:17:23 AM
Boehringer Ingelheim Corporation Plans To Cut Up To 600 Jobs 9/23/2014 6:42:19 AM
Boehringer Ingelheim Corporation Will Pay Up To $600 Million For CureVac GmbH Lung Cancer Vaccine 9/18/2014 6:21:48 AM
Boehringer Ingelheim Corporation Release: Type 2 Diabetes: Investigational Empagliflozin/Linagliptin Combination Tablet Shows Sustained Reduction In Blood Glucose In Phase 3 Study 9/16/2014 9:22:37 AM
12345678910...
//-->